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Abstract 
Aims 
Global Registry of Acute Coronary Events (GRACE) risk score (GRS), a powerful predictor 
of prognosis after ACE, does not include a glucometabolic measure. We investigate whether 
2 hour post-load plasma glucose (2h-PG) could improve GRS based prognostic models in 
ACE patients without known diabetes mellitus (DM). 
Methods 
Retrospective cohort study of 1056 ACE survivors without known DM who had fasting (FPG) 
and 2h-PG measured pre-discharge. Death and non-fatal myocardial infarction (MI) were 
recorded as major adverse cardiac events (MACE) during follow up. GRS for discharge to 6 
months was calculated. Cox proportional-hazards regression was used to identify predictors 
of event free survival. The predictive value of 2h-PG alone and combined with GRS was 
estimated using Likelihood ratio test, Akaike’s Information criteria, continuous net 
reclassification improvement (NRI>0) and integrated discrimination improvement (IDI). 
Results 
During 40.8 months follow up 235 MACEs (22.3%) occurred, more frequently in the upper 
2h-PG quartiles. 2h-PG, but not FPG, adjusted for GRS independently predicted MACE (HR 
1.091; 95 % CI 1.043-1.142; p=0.0002). Likelihood ratio test showed that 2h-PG significantly 
improved the prognostic models including GRS (χ2=20.56, 1 df, p=0.000). Models containing 
GRS and 2h-PG yielded lowest corrected Akaike’s Information criteria, compared to that with 
only GRS. 2h-PG, when added to GRS, improved net reclassification significantly (NRIe>0 
6.4%, NRIne>0 24%, NRI>0 0.176, p = 0.017 at final follow up). 2h-PG, improved integrated 
discrimination of models containing GRS (IDI of 0.87%, p=0.008 at final follow up). 
Conclusion 
2h-PG but not FPG is an independent predictor of adverse outcome after ACE even after 
adjusting for the GRS. 2h-PG, but not FPG, improves the predictability of prognostic models 
containing GRS. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
Key words: 
Acute coronary syndrome, myocardial infarction, GRACE, Global Registry of Acute Coronary 
Events, prognosis, diabetes, oral glucose tolerance test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
Introduction  
The Global Registry of Acute Coronary Events (GRACE) risk score (GRS) for mortality and 
re-infarction up to 6 months post-discharge is a powerful predictor of short and long-term 
prognosis after acute coronary syndrome (ACS).1-4 Although it is well established that post-
ACS prognosis is worse in patients with known diabetes mellitus (DM) than in those without, 
DM is not included as a variable in the GRS model.  
 
Several studies show that hyperglycaemia, newly diagnosed after myocardial infarction (MI) 
on admission plasma glucose (APG), fasting plasma glucose (FPG), admission glycosylated 
haemoglobin (HbA1c) and oral glucose tolerance test (OGTT), in patients without known DM 
adversely affects long term prognosis. None of these studies have included GRS or all of its 
components in their models to predict outcomes or demonstrated an independent effect of 2 
hour post load glucose (2h-PG) on prognosis. A few studies that have included GRS in 
addition to the glycaemic indices in their prognostic models have yielded variable results.5-16 
Thus it is still unclear as to which glycaemic index best predicts prognosis after MI in patients 
without known diabetes and whether 2h-PG, in addition to the GRS, independently predicts 
post-MI prognosis.  
 
In the present study, we investigate the value of FPG and 2h-PG in addition to GRS in 
predicting major adverse cardiac events (MACEs) in patients with MI but without known DM 
and the potential incremental prognostic value of adding FPG and 2h-PG to to models 
including GRS only. 
 
Methods 
We retrospectively analysed data, prospectively collected for a mandatory national audit, the 
Myocardial Infarction National Audit Project (MINAP), on all consecutive MI survivors without 
known DM, admitted between November 2005 and October 2008, who underwent pre-
discharge oral glucose tolerance test (OGTT) as part of routine clinical care and were 
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 5 
followed up.17 This observational study includes all patients for whom FPG, 2h-PG and the 
GRS were available. 
 
Data on age, gender, risk factors for CAD, past medical history, pre-hospital and discharge 
medications, troponin I levels, heart rate, systolic blood pressure, creatinine level, presence 
of congestive heart failure, previous history of MI, revascularisation status and presence of 
ST-segment depression were recorded. Web-based GRS calculator was used to calculate 
the risk of death or MI from discharge to 6 months for each patient. Patients with pre-existing 
diabetes were excluded. Patients were classified as having pre-admission DM if the patient 
had been informed of the diagnosis by a physician or was on treatment. HbA1c was not 
used for diagnosing pre-hospital diabetes as it was not recommended in contemporary 
guidance.18,19 FPG (after an overnight fast of ≥8 hours) and OGTT (venous plasma glucose 
measured 2 hours after administration of 75g glucose (2-h PG) in 200 ml water) were done 
on/after the third day of admission on consecutive patients without known DM. Patients who 
died before or did not tolerate the OGTT and were transferred to other centres before OGTT 
were excluded. Discharge was not delayed for the OGTT. Plasma glucose was 
enzymatically determined using the glucose oxidase method. Intravenous glucose solutions 
were not allowed, but anti-adrenergic agents were used if clinically indicated. Clinically 
unstable patients were tested later. The patients with impaired glucose tolerance (IGT) and 
new diabetes mellitus (NDM) were referred to the diabetologists for appropriate out-patients 
management. 
 
Participants were followed for up to 5 years (median 3.4years) for outcomes. Completeness 
of follow up was ensured by manual review of hospital and general practice records. The first 
occurrence of a MACE defined as death or non-fatal re-infarction, the events that the GRS 
predicts, was obtained from patient records. Mortality data was collected from the hospital 
care records for patients who died in hospital. For patients who died in the community, 
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 6 
mortality data was obtained from the general practitioner medical records confirmed by the 
office of public health intelligence. 
 
Permission was sought from the East Yorkshire and North Lincolnshire Research Ethics 
Committee to analyse the data. As the study retrospectively analysed routinely collected 
anonymised data on standard clinical practice to contribute to a National Audit database, the 
Committee waived the need for formal ethical approval and patient consent.17  
 
Statistical analysis 
Continuous variables are presented as medians (inter-quartile range) and categorical 
variables as counts and proportions (%). Baseline characteristics are presented as quartiles 
of 2h-PG. The differences were compared between groups using the one-way analysis of 
variance and Kruskal-Wallis test for parametric and non-parametric data respectively for 
continuous variables and chi-squared test for categorical variables. Event free survival was 
estimated in the 4 quartiles of 2h-PG from Kaplan–Meier curves that were compared using 
the Log-rank test. Cox proportional-hazards regression modelling was used to analyse the 
effect of several variables on event free survival. All covariates known to affect prognosis 
after MI including gender, smoking status, hypercholesterolaemia, hypertension, history of 
previous acute MI, diagnosis at discharge, discharge prescription of aspirin, clopidogrel, 
beta-blockers, angiotensin-converting enzyme inhibitors and statins, in-patient 
revascularisation status, GRS for 6 months from discharge for death and MI, FPG and 2h-
PG were “entered” into the model. The GRS variables (i.e. age, resting heart rate, systolic 
blood pressure on arrival, creatinine, congestive heart failure, history of myocardial 
infarction, ST-segment depression, elevated troponin, and in-hospital revascularisation) 
were not entered separately. Results are reported as hazard ratios (HRs) with associated 
95% confidence intervals (CIs). Multicollinearity was examined using variance inflation factor 
(VIF) (MedCalc Statistical Software version 17.0.4, Ostend, Belgium) and variables with 
VIF<4 were included in the same model.  
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Nested models were compared using χ2 likelihood ratio tests to determine whether the 
logistic regression model that included GRS and FPG or 2h-PG provided a significantly 
better fit than those with GRS alone. Comparison of nested and non-nested models 
including GRS, or its combination with FPG or 2h-PG was performed by calculating 
corrected Akaike’s information criterion (AICc), delta-AICc (δAIC)c, and Akaike weights (wi), 
to estimate the probability that a given model is the “best” fitting model of those studied.20  
 
Logistic regression models using the above covariates along with GRS, FPG and 2h-PG 
individually and in combination were used to generate predicted probabilities of MACE. The 
incremental predictive value from adding FPG and 2h-PG to models with GRS was analyzed 
from these predicted probabilities using several measures of improvement in discrimination: 
increase in the area under the receiver-operating characteristic (ROC) curve (AUC) 
(MedCalc Statistical Software version 17.0.4, Ostend, Belgium), category-free continuous 
net reclassification improvement (cNRI>0) and integrated discrimination improvement (IDI). In 
the absence of clearly pre-defined clinical risk thresholds for the models including GRS, 
categorical NRI was not used. The event NRI (NRIe) was defined as net percentage of 
persons with the event of interest correctly assigned a higher predicted risk and non-event 
NRI (NRIne) as net percentage of persons without the event of interest correctly assigned a 
lower predicted risk. The overall NRI defined as sum of the net proportion of persons with 
and without the event of interest correctly assigned a different predicted risk is reported as a 
number. The IDI was equal to the increase in discrimination slope defined as the mean 
difference in predicted risks between those with and without events.  
 
Results  
The 1056 patients, included in the study, were divided into quartiles of 2h-PG (Q1, ≤6.5 
mmol/l, Q2, 6.6-8.1 mmol/l, Q3, 8.2-10.4 mmol/l and Q4, >10.4 mmol/l) (Table 1) The 
patients in the upper quartiles were older, had more risk factors, were less frequently on 
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 8 
clopidogrel, had higher heart rate and creatinine, more frequent heart failure, ST segment 
depression and high-risk GRS, higher mean GRS and FPG.  
   
Outcomes  
During the median follow-up of 40.8 months (range 6-60 months) there were 235 MACEs 
(22.3%), 112 deaths (10.6%) and 123 non-fatal re-infarctions (11.6%). MACE was more 
frequent in the upper glucose quartiles (Table 1). Death and non-fatal re-infarction increased 
with increasing quartiles of 2h-PG even in those where the level of 2h-PG did not cross the 
conventional threshold for the diagnosis of DM (Fig. 1). On Cox proportional hazard 
regression analysis 2h-PG and GRS, but not FPG, were consistently independent predictors 
of MACE at the final follow up when included in the same model as GRS (Table 2).  The risk 
of MACE increased by 9% for each mmol/l rise in 2h-PG.  
 
Nested models were compared using likelihood ratio tests to determine whether logistic 
regression models that included GRS and FPG or 2h-PG provided a significantly better fit 
than that limited to the GRS. This showed that addition of the 2h-PG as a continuous 
variable significantly improved the ability of a model including GRS score to predict MACE at 
all time points during follow up (Table 3). Addition of FPG did not improve the model fit.  
Comparing models containing GRS alone, GRS with FPG and GRS with 2h-PG, the later 
yielded the lowest corrected AIC, highest Akaike’s weight and evidence ratio compared to 
that with only GRACE score (Table 3). This suggests that the model with GRACE score and 
2h-PG is more likely to be the “best” fitting model compared to the other models tested. 
 
Entering 2h-PG, but not FPG, into a logistic regression model containing GRACE score 
alone significantly improved the net reclassification of later model in predicting events during 
follow up (Table 4). Using continuous NRI (NRI>0) 2h-PG improved reclassification by 6.4% 
for those with events and by 24% for those without, resulting in a significant overall 
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 9 
improvement in net reclassification (NRI 0.176, p = 0.017 at final follow up). The model 
including the GRS and 2h-PG seems to predict a lower risk of MACE than that with GRS 
only both in the event and non-event groups. This reduction in the predicted risk, results in 
24% improvement in net reclassification in the non-event group.  Addition of FPG did not 
improve reclassification .The addition of 2h-PG, but not FPG, to a model including GRS 
improved integrated discrimination at all time points during follow up (Table 4). It yielded an 
IDI of 0.87%, p=0.008 at final follow up.  
 
The c-statistic was 0.746 (95% CI 0.719 to 0.772, p <0.0001) for the prognostic model 
containing the GRS only, 0.719 (95% CI 0.691 to 0.746, p<0.0001) for the model containing 
2h-PG only and 0.754 (95% CI 0.726 to 0.779, p <0.0001) for the model including GRS and 
2h-PG. The AUC for the GRS-only was better than the 2h-PG only model (δAUC 0.0274, p = 
0.045). The c-statistic did not increase significantly when 2h-PG was added to the GRS only 
model (δAUC 0.00744, p = 0.165) but did so when GRS was added to the 2h-PG only model 
(δAUC 0.0348, p = 0.002). This suggests that GRS, as expected, is a more powerful 
predictor of events than 2h-PG. 
 
 
Discussion  
This study shows that 1) 2h-PG, but not FPG, independently predicts prognosis after ACS 
after adjusting for the GRS and 2) 2h-PG, but not FPG, improves the ability of models 
containing GRS to predict long-term adverse events after an ACS in patients without known 
DM.  
 
The GRS is a powerful predictor of prognosis after MI at different time points up to 4 years.1-4 
Even though it is well established that patients with ACS and DM have poorer outcomes 
than those without; the GRS does not include DM or any of the glycaemic indices as a 
variable in the model. In the GRACE, DM independently predicted in-hospital2 but not the 6-
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month post-discharge mortality.3 The initial logistic regression models developed from 
GRACE to predict prognosis incorporated several variables including DM as a dichotomous 
categorical variable. This model was reduced to include only the eight most predictive 
variables to make it clinically usable.2 DM and other variables were removed as the c 
statistics of models with and without these variables were similar.2,3 In the GRACE, FPG 
increased the risk of in-hospital mortality both when FPG was used to group patients and 
when used as continuous variable irrespective of a history of DM.5 The 6 months post-
discharge mortality was high only if FPG was in the diabetic range.5  
 
Almost all studies suggesting that FPG, APG, HbA1c or AGT, are independent predictors of 
adverse prognosis after ACS have not included the GRS (or all its individual components) 
within their regression models. The results, in a few studies that did, are variable. When 
adjusted for GRS, FPG, APG and HbA1c have independently predicted outcomes in some 
6,8,9,12,15 but not other5,7,11,13,14,16 studies. APG, FPG and HbA1c improved the predictive ability 
of models containing GRS in some9,12,21 but not all studies10,13,14. This is the only study to 
show that 2h-PG independently predicts prognosis after ACS after adjusting for the GRS and 
improves the ability of models containing GRS to predict prognosis. 
 
In contrast to our study, Aronson et al showed that in patients without known diabetes FPG, 
adjusted for the GRS, predicted mortality after MI and improved the prognostic models 
containing GRS.9 That study included mainly (73%) STEMI patients, measured FPG within 
24 hours of admission and 2h-PG were not measured. Only 44% of our patients had STEMI 
and FPG and 2h-PG were measured at 3-5 days. As the troponin in the GRS is not a 
continuous variable it does not reflect the prognostic effect of the extent of myonecrosis. 
Glucose levels are higher when measured within the first 24-48 hours of MI than later and 
after STEMI compared to NSTEMI.22,23 The higher FPG in these STEMI patients when 
combined with GRS, a variable not influenced by the volume of myonecrosis, may have 
affected the model favourably improving its performance. In addition, it is unclear whether 
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FPG would remain an independent predictor if 2h-PG was included in the models in this 
study. This could explain the difference in the two studies. The increased macrovascular 
morbidity associated with higher 2h-PG rather than FPG as seen in this study may be 
related to progression of atherosclerosis demonstrated with post-challenge rather than 
fasting hyperglycaemia.24-28  
 
Without HbA1c, we do not have all the glycaemic indices to compare their effect on 
prognosis. HbA1c has predicted post-MI prognosis in some 8,29-31 but not all studies.32-36 The 
relative ability of APG, FPG, 2h-PG and HbA1c to predict post MI prognosis in patients 
without previously known diabetes has rarely been studied.32,35,37 In the EUROASPIRE 
IV,35,38 neither FPG nor HbA1c predicted the primary outcome, whereas the 2h-PG did. In 
another study,32 HbA1c ≥6.5%, in the same model as OGTT, did not show any significant 
increase in mortality. However, there was significantly increased mortality in patients with 
HbA1c <6.5% categorized as newly diagnosed DM by OGTT.  Kowalczyk et al37 suggest 
that the HbA1c may be useful in further risk stratifying patients diagnosed with IGT and NDM 
but do not report the effect of HbA1c on prognosis of patients without. Sattar et al39 suggest 
that HbA1c and FPG are better than OGTT for cardiovascular disease risk prediction citing 
two studies40,41 to argue in favour. The first,40 specifically excluded people with history of 
CVD at baseline. The second,41 DETECT-2, looks at the relation of FPG and HbA1c 
prevalence of retinopathy, a microangiopathy, in epidemiological setting. Thus both these 
studies included populations very dissimilar to our study. The EUROSPIRE IV and 
SWEETHEART registry42 support the use of OGTT for predicting prognosis in these high risk 
patients. 
 
The c-statistic did not change significantly when 2h-PG was added to a model containing 
GRS. It is unsurprising that adding GRS to the model containing 2h-PG did. The increment 
in the c-statistic, used to quantify the added value offered by the new biomarker, is overly 
conservative and the ΔAUC depends on the performance of the underlying clinical model i.e. 
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good clinical models are harder to improve on.43 Improving models containing powerful 
variables as the GRS may be difficult. To deal with this anomaly, Pencina et al.44,45 devised 
the IDI and NRI>0, for evaluating reclassification with novel biomarkers. These matrices 
improved when 2h-PG is added to GRS. The larger improvement in net reclassification in the 
non-event group when adding 2h-PG to the GRS may suggest that the 2h-PG tempers down 
the risk predicted by the GRS alone in these patients.   
 
As we aimed to evaluate whether adding FPG and/or 2h-PG improved prediction of post-MI 
prognosis by models containing GRS, we restricted ourselves to end-points predicted by the 
GRS i.e. death and non-fatal reinfarction as the only study end-points. We also entered the 
GRS as a composite rather than its individual covariates separately in the logistic regression 
analysis, as we wanted to see whether FPG and/or 2h-PG could improve the models 
containing GRS. 
 
Limitations 
Being an observational longitudinal cohort study using retrospective analysis of prospectively 
collected data from a single centre, it has its limitations. Although national death register was 
not consulted directly, there is no reason to doubt the accuracy of a linked general practice 
database used. As the study includes only the re-infarctions admitted to the local hospital, a 
few admitted to other hospitals may have been missed. Although every effort was made to 
ensure completeness of the data, information not recorded could not be used in statistical 
models. Exclusion of small number of patients, albeit for valid reasons, and mainly 
Caucasian study population could affect the generalizability of the results. The effect of 
random glycaemic fluctuations or stress hyperglycaemia on the results can not be excluded. 
As OGTT was not repeated pre- or post- discharge, it is uncertain whether random 
fluctuation in glycaemia or stress hyperglycaemia affected results. However, OGTT done at 
or after 5 days seems to reliably predict long term glucometabolic state.46,47 As pre-discharge 
post-challenge hyperglycaemia, irrespective of its pathophysiological mechanism, predicted 
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outcomes in post-MI patients, the reproducibility of these measurements and its relation to 
long term glucometabolic status, though important in establishing a diagnosis of MI, may be 
less relevant when assessing prognostic risk. 
 
Conclusion 
This study suggests that in patients without known diabetes 2h-PG, but not FPG, is an 
independent predictor of adverse outcome after ACS even after adjusting for the GRS. The 
2h-PG, but not FPG, improves the ability of models including GRS to predict long-term post-
ACS prognosis. As the choice of diagnostic tests for detection of glycaemic abnormalities in 
this population is hotly debated it may be reasonable to suggest that the most important test 
would be the one that determines long term prognosis after ACS i.e. 2h-PG rather than the 
one deemed sufficient for use in the low-risk general population for epidemiological purposes 
even if simpler and more feasible i.e. HbA1c. This is especially so when clear evidence in 
favour HbA1c against 2h-PG in this high risk population is lacking. The 2h-PG should at 
least be considered as a marker of post-MI prognosis in these patients. 
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Figure 1. The event free survival in the quartiles of 2 hour post load glucose. 
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Table 1. Baseline characteristics of the study population categorised by quartiles of 2h post load 
glucose.  
 
Q1 ≤6.5 
(n=274) 
Q2 6.6-8.1 
(n=261) 
Q3 8.2-10.4 
(n=259) 
Q4 >10.4 
(n=262) 
p 
Male n (%) 186(67.9) 186(71.3) 193(74.5) 192(73.3) 0.344 
Current smoker n (%) 114(41.6) 83(31.8) 84(32.4) 82(31.3) 0.034 
Hypertension n (%) 80(29.2) 100(38.3) 110(42.5) 105(40.1) 0.009 
Hypercholesterolaemia n (%) 45(16.2) 69(26.4) 57(22.0) 62(23.7) 0.039 
Previous AMI n (%) 35(12.8) 45(17.2) 47(18.2) 54(20.6) 0.107 
Known IHD n (%) 39(14.2) 51(19.5) 52(20.1) 58(22.1) 0.113 
CVA 7(2.6) 8(3.1) 15(5.8) 22(8.5) 0.006 
Normal LVEF 139(50.7) 108(41.4) 104(40.2) 108(41.2) 0.045 
Diagnosis NSTEMI n (%) 163(59.5) 144(55.2) 131(50.6) 152(58.0) 0.176 
Discharge medications  
  Aspirin n (%) 267(97.5) 250(95.8) 241(93.1) 245(93.5) 0.070 
  Clopidogrel n (%) 251(91.6) 243(93.1) 220(84.9) 235(89.7) 0.013 
  Beta-blocker n (%) 196(71.5) 186(71.3) 190(73.4) 204(77.9) 0.287 
  ACEI/ARB n (%) 210(76.6) 204(78.2) 208(80.3) 214(81.7) 0.489 
  Statin n (%) 237(86.5) 223(85.4) 219(84.6) 228(87.0) 0.853 
  
GRACE Variables  
  Age(years; median; IQR) 59.5(18.8) 63.5(17.4) 66.3(17.5) 68.3(18.2) <0.001 
HR bpm (median, IQR) 73(24) 76(27) 74(25) 81(28) 0.005 
SBP (median, IQR) 137(31) 140(38) 139(38) 140(36.5) 0.196 
Creatinine µmol/l(median, IQR) 94(21) 96(23) 100(24) 102(24.5) <0.001 
HF 8(2.92) 10(3.8) 11(4.25) 23(8.8) 0.009  
ST segment depression 174(63.5) 197(75.5) 195(75.3) 199(75.9) <0.001 
Troponin rise 273(99.6) 260(99.6) 256(98.8) 258(98.5) 0.369 
Cardiac Arrest 6(2.2) 11(4.2) 12(4.6) 13(5.0) 0.349 
  
GRACE score  
Admission-6m Death (Median, IQR) 103(39) 114(40) 115(37) 119(43.3) <0.001 
Admission-6m Death/MI (Median, IQR) 154(48) 166(46) 167(48) 167(54.3) <0.001 
Discharge-6m Death (Median, IQR) 104(42) 115(39) 119(38) 123(42) <0.001 
Discharge-6m Death/MI (Median, IQR) 113(37) 113(37) 113(37) 131(45) <0.001 
  
GRACE Risk  
High 97(35.4) 117(44.8) 131(50.6) 149(56.9) <0.001 
Intermediate  89(32.5) 95(36.4) 88(34.0) 88(33.6) 0.810 
Low 88(32.1) 49(18.8) 40(15.4) 25(9.5) <0.001 
  
Glucometabolic category  
NGT 267(97.5) 198(75.9) 0(0) 0(0) <0.001 
IGT 0(0) 56(21.5) 253(97.7) 61(23.3) <0.001 
NDM 7(2.6) 7(2.7) 6(2.3) 209(79.8) <0.001 
FPG (mmol/l; median; IQR) 4.9(0.6) 5(0.6) 5.1(0.8) 5.5(1.13) <0.001 
2HBG (mmol/l; median; IQR) 5.6(1.3) 7.4(0.7) 9.2(1.4) 12.3(3) <0.001 
      
MACE 30(10.9) 64(24.5) 67(25.9) 74(28.2) - 
  Deaths 14(5.1) 24(9.2) 39(15.1) 35(13.4) - 
  Re-infarctions 16(5.8) 40(15.3) 28(10.8) 39(14.9) - 
 
Table 1
Table 2. Candidate predictors of event-free survival. 
 
Covariate HR 95% CI P 
Grace Score 1.01 1.01-1.02 <0.0001 
2h-PG 1.09 1.04-1.14 0.000 
Hypercholesterolaemia 0.66 0.47-0.92 0.014 
Previous MI 1.50 1.05-2.14 0.024 
Discharged without BB 1.39 1.02-1.88 0.035 
FPG 0.85 0.71-1.01 0.063 
Discharged without clopidogrel 1.35 0.95-1.93 0.098 
Hypertension 1.25 0.95-1.64 0.115 
Previous Revascularisation 1.35 0.90-2.01 0.149 
Discharged without ACEI 1.29 0.91-1.83 0.154 
Discharged without Aspirin 1.37 0.86-2.19 0.184 
Female Gender 1.14 0.85-1.51 0.379 
Discharge Diagnosis of STEMI 1.13 0.86-1.49 0.381 
Discharged without statin 0.90 0.58-1.38 0.619 
Current Smoker 0.94 0.70-1.25 0.655 
 
Table 2
Table 3. Akaike’s Information criteria and Likelihood ratio test to determine the best fitting model for 
predicting MACE. 
 
Akaike’s Information criteria Likelihood ratio test 
Model AICc δAICc 
Relative 
Likelihood wi wj/wi  Model Χ2 df p 
GRS 1006.46 8.22 0.02 0.02 2.65 GRS vs.       
GRS+2HBS 998.24 0.00 1.00 0.98 162.07 GRS+2HBS 20.56 1 0.000 
GRS+FBS 1008.41 10.18 0.01 0.01 1.00 GRS+FBS 0.21 1 0.645 
 
AICc, corrected Akaike’s information criteria; δAICc, delta AICc is a measure of each model relative to 
the best model; wi, Akaike weights, the ratio of δAICc values for each model relative to the whole set;  
wj/wi, Evidence ratios compare the wi of the “best” model and competing models to test the extent to 
which it is better than another. 
 
Table 3
Table 4. Net reclassification improvement for model improvement with the addition of 2h-PG or FPG 
to GRACE score alone. 
 
 Grace score vs Grace score and 2h-PG  Grace score vs Grace score and FPG 
 NRIe NRIne Total p NRIe NRIne Total p 
UP 110 312 422  143 481 624  
DWN 125 509 634  92 340 432  
TOTAL 235 821 1056  235 821 1056  
NRI>0 -0.064 0.240 0.176 0.017 0.217 -0.172 0.045 0.541 
 
 IDIe IDIne Total p IDIe IDIne Total p 
Final 0.0067 -0.0019 0.0087 0.008 0.0000 0.0000 0.0000 0.449 
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Abstract 
Aims 
Global Registry of Acute Coronary Events (GRACE) risk score (GRS), a powerful predictor 
of prognosis after ACE, does not include a glucometabolic measure. We investigate whether 
2 hour post-load plasma glucose (2h-PG) could improve GRS based prognostic models in 
ACE patients without known diabetes mellitus (DM).  
Methods 
Retrospective cohort study of 1056 ACE survivors without known DM who had fasting (FPG) 
and 2h-PG measured pre-discharge. Death and non-fatal myocardial infarction (MI) were 
recorded as major adverse cardiac events (MACE) during follow up. GRS for discharge to 6 
months was calculated. Cox proportional-hazards regression was used to identify predictors 
of event free survival. The predictive value of 2h-PG alone and combined with GRS was 
estimated using Likelihood ratio test, Akaike’s Information criteria, continuous net 
reclassification improvement (NRI>0) and integrated discrimination improvement (IDI). 
Results 
During 40.8 months follow up 235 MACEs (22.3%) occurred, more frequently in the upper 
2h-PG quartiles. 2h-PG, but not FPG, adjusted for GRS independently predicted MACE (HR 
1.091; 95 % CI 1.043-1.142; p=0.0002). Likelihood ratio test showed that 2h-PG significantly 
improved the prognostic models including GRS (χ2=20.56, 1 df, p=0.000). Models containing 
GRS and 2h-PG yielded lowest corrected Akaike’s Information criteria, compared to that with 
only GRS. 2h-PG, when added to GRS, improved net reclassification significantly (NRIe>0 
6.4%, NRIne>0 24%, NRI>0 0.176, p = 0.017 at final follow up). 2h-PG, improved integrated 
discrimination of models containing GRS (IDI of 0.87%, p=0.008 at final follow up).  
Conclusion  
2h-PG but not FPG is an independent predictor of adverse outcome after ACE even after 
adjusting for the GRS. 2h-PG, but not FPG, improves the predictability of prognostic models 
containing GRS. 
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